Oscar krijgsman
机构: Principle Bioinformatician, Neogene Therapeutics
每年引用次数
引用次数
引用: 7,953
H-指数: 35
I10-指数 : 62
出版物: 117
Dissecting the Grey Zone Between Follicular Lymphoma and Nodal Marginal Zone Lymphoma using Morphological and Genetic Features
O. Krijgsman , L. Braaf , B. Ylstra , Max Beijert
The Journal of Pathology 229
2013
Genome Wide Dna Alterations of Stage Ii Colon Cancer in Patients with and Without Relapse Assessed by Array Cgh
O. Krijgsman , B. Ylstra , B. Carvalho , E.J.T.H. Belt
Cellular Oncology 32 ( 3) 208 -208
2010
High CD8+ tumour infiltrating lymphocyte density associates with unfavourable prognosis in oesophageal adenocarcinoma following poor response to neo-adjuvant chemoradiotherapy.
A. Broeks , J.W van Sandick , F.E.M. Voncken , M.N. Sosef
Histopathology
2021
Dissecting the gray zone between follicular lymphoma and marginal zone lymphoma using morphological and genetic features
O. Krijgsman , P. Gonzalez , O. B. Ponz , M. G. M. Roemer
Haematologica 98 ( 12) 1921 -1929
8
2013
LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial
L. Zuur , J.L. Vos , J.B. Elbers , O. Krijgsman
Annals of Oncology 31
1
2020
0063 Comparison of MammaPrint and TargetPrint results with clinical parameters in German patients (PATH) with early stage breast cancer
G. Kunz , T. Dimpfl , C. Jakisch , R. Buttner
The Breast 18
2009
30 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial)
E.A. Rozeman , K. Sikorska , B.A. van de Wiel , L.F. Fanchi
Annals of Oncology 29
3
2018
OpACIN-neo: A multicenter phase II study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO)
CU Blank , EA Rozeman , AM Menzies , BA Van de Wiel
Annals of Oncology 29
9
2018
Use of a gene profile to identify molecular subtypes of breast cancer.
W. Zwart , F. De Snoo , O. Krijgsman , P. Roepman
Journal of Clinical Oncology 29 537 -537
2011
Combined use of MammaPrint and molecular subtyping profile (BluePrint) to identify subgroups with marked differences in response to neoadjuvant treatment.
L. Stork-Sloots , F. De Snoo , P. Roepman , O. Krijgsman
Journal of Clinical Oncology 29 10613 -10613
2011
High lymph node yield is related to microsatellite instability in colon cancer.
E. J. Th. Belt , E. A. te Velde , O. Krijgsman , R. P. M. Brosens
Annals of Surgical Oncology 19 ( 4) 1222 -1230
55
2012
Presence of a 34-gene signature is a favorable prognostic marker in squamous non-small cell lung carcinoma.
W. S. M. E. Theelen , O. Krijgsman , K. Monkhorst , T. Kuilman
Journal of Translational Medicine 18 ( 1) 1 -12
1
2020
Molecular Subtype Profile Reveals Therapy Predictive Power.
F. de Snoo , O. Krijgsman , P. Roepman , R. Bender
Cancer Research 69 6131 -6131
2009
Biological Functions of Genes in the 70-Gene MammaPrint Tumor Expression Profile Reflect Molecular Mechanism of Tumor Metastasis.
A. Glas , S. Tian , P. Roepman , O. Krijgsman
Cancer Research 69 6146 -6146
2009
Basal-, Luminal-, and HER2- Molecular Subtype, and the MammaPrint 70-Gene Signature as Predictors of Response to Neoadjuvant Chemotherapy (NCT) with Docetaxel, Doxorubicin, Cyclophosphamide (TAC), or AC andNab-Paclitaxel and Carboplatin +/- Trastuzumab in Patients (Pts) with Stage II-III and Inflammatory Breast Cancer (BC).
G. Somlo , S. Lau , P. Frankel , C. Garberoglio
Cancer Research 69 2026 -2026
1
2009
18-months relapse-free survival (RFS) and biomarker analyses of OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant (neoadj) ipilimumab (IPI) + nivolumab (NIVO) in stage III melanoma
E.A. Rozeman , A.M. Menzies , O. Krijgsman , E.P. Hoefsmit
Annals of Oncology 30
10
2019
Package ‘focalCall’
Oscar Krijgsman , Maintainer Oscar Krijgsman , Suggests RUnit , Preprocessing biocViews Microarray
2014
Cooperative Targeting of Immunotherapy-Resistant Melanoma and Lung Cancer by an AXL-Targeting Antibody-Drug Conjugate and Immune Checkpoint Blockade.
Oscar Krijgsman , Maarten L. Janmaat , Maarten A. Ligtenberg , Mischa Houtkamp
Cancer Research 81 ( 7) 1775 -1787
2021
Genomic aberrations relate early and advanced stage ovarian cancer
Afra Zaal , , Wouter J. Peyrot , P. M. J. J. Berns
Cellular Oncology 35 ( 3) 181 -188
7
2012